

Laboratory Service Report

1-800-533-1710

Patient Name VALIDATIONSOFT,CLLMREPORT	Patient ID SA00060999	Age 62	Gender M	Order # SA00060999
Ordering Phys CLIENT,CLIENT				DOB 10/10/1950
Client Order # SA00060999	Account Information			Report Notes
Collected 08/25/2013 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 10/15/2013 14:28	Rochester, MN 55901			

Reference Perform Unit Test Flag Results Value Site* CLL Monitoring, MRD Detection, B **RECEIVED:** 08/26/2013 15:19 **REPORTED:** 08/27/2013 10:30 MCR Microscopic Description A submitted Wright-Giemsa slide and a Wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined. Supplemental PDF Report available at: https://test.mmlaccess.com/Reports/C7028846-xGiWKiIZaE.ashx Special Studies: MCR WBC: $10.0 \times 10(9)/L$ %Lymphs (CBC/automated differential): 50% #Lymphs (CBC/automated differential): 5.0 x 10(9)/L Results: B-cells: Monotypic kappa Express: CD19, CD20 (dim), CD5, CD23, CD45. MRD analysis: 5% gated lymphoid events; 0.5% total analyzed events Quality Assessment: Specimen received within validated quidelines. Flow cytometry analysis performed with antibodies to the following antigens: CLL MRD: CD5, CD19, CD20, CD23, CD45 and kappa and lambda surface light chains. Final Diagnosis: MCR Peripheral blood, flow cytometric immunophenotyping: A CD5-positive, kappa light chain-restricted B-cell population is detected. MRD = 0.50%. Comment: Minimal residual disease (MRD) analysis is intended to

Minimal residual disease (MRD) analysis is intended to detect small clonal populations of residual chronic lymphocytic leukemia (CLL) cells following chemotherapy or bone marrow transplantation. This CLL MRD assay is validated to a sensitivity level of 0.01%, or 1 in 10,000 white blood cells. Reviewed by: Steven Bashynski 2013.08.27 10:30:05

Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend on Last Page of Report

	Collection Date and Time	Report Status
VALIDATIONSOFT,CLLMREPORT	08/25/2013 00:00	Final
Page 1 of 2		>> Continued on Next Page >>



Laboratory Service Report

1-800-533-1710

Patient Name VALIDATIONSOFT,CLLMREPORT	Patient ID SA00060999	Age 62	Gender M	Order # SA00060999
Ordering Phys CLIENT,CLIENT		·	·	DOB 10/10/1950
Client Order # SA00060999	Account Information			Report Notes
Collected 08/25/2013 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 10/15/2013 14:28	Rochester, MN 55901			

Test Flag Results Unit Value Site*

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
VALIDATIONSOFT, CLLMREPORT	08/25/2013 00:00	Final
Page 2 of 2		** End of Report **

^{*} Report times for Mayo performed tests are CST/CDT



Performing Site:

Mayo Clinic Laboratories - Rochester Main Campus 200 First Street SW, Rochester MN 55905 Franklin R. Cockerill, M.D. Lab Director

Phone: 800-533-1710

http://www.mayomedicallaboratories.com

VALIDATIONSOFT, CLLMREPORT

MEDICAL RECORD # (PATIENT ID) SA00060999

DOB 10/10/1950 CLIENT ID/WARD 7028846 ORDER# B326000305 CLIENT/NAME WARD DLMP Rochester SEX Male CLIENT ORDER # SA00060999 SA00060999 DATE COLLECTED 8/25/2013 12:00 AM CLIENT MRN CITY, ST, ZIP Rochester REQUESTED BY CLIENT CLIENT MN 55901 DATE RECEIVED 8/26/2013 3:19 PM DATE REPORTED 8/27/2013 10:30 AM

CLL Monitoring, MRD Detection, B

Final Diagnosis:

Peripheral blood, flow cytometric immunophenotyping:

A CD5-positive, kappa light chain-restricted B-cell population is detected. MRD = 0.50%.

Minimal residual disease (MRD) analysis is intended to detect small clonal populations of residual chronic lymphocytic leukemia (CLL) cells following chemotherapy or bone marrow transplantation. This CLL MRD assay is validated to a sensitivity level of 0.01%, or 1 in 10,000 white blood cells.

Reviewed by: Steven Bashynski 2013.08.27 10:30:05

Special Studies:

WBC: $10.0 \times 10(9)/L$

%Lymphs (CBC/automated differential): 50% #Lymphs (CBC/automated differential): 5.0 x 10(9)/L

Results:

B-cells: Monotypic kappa

Express: CD19, CD20 (dim), CD5, CD23, CD45.

MRD analysis: 5% gated lymphoid events; 0.5% total analyzed events

Quality Assessment: Specimen received within validated guidelines.

Flow cytometry analysis performed with antibodies to the following antigens: CLL MRD: CD5, CD19, CD20, CD23, CD45 and kappa and lambda surface light chains.

Microscopic Description:

A submitted Wright-Giemsa slide and a Wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined.

Disclaimer:

Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.